Part VI: Summary of the risk management plan

Summary of risk management plan for Clopidrion (clopidogrel hydrogen sulfate)

This is a summary of the risk management plan (RMP) for Clopidrion. The RMP details important risks of Clopidrion, how these risks can be minimized, and how more information will be obtained about Clopidrion's risks and uncertainties (missing information).

Clopidrion's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Clopidrion should be used.

Important new concerns or changes to the current ones will be included in updates of Clopidrion's RMP.

I. The medicine and what it is used for

Clopidrion is authorised for prevention of blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death) (see SmPC for the full indication). It contains clopidogrel hydrogen sulfate as the active substance and it is given by mouth.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Clopidrion, together with measures to minimise such risks and the proposed studies for learning more about Clopidrion's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Clopidrion is not yet available, it is listed under ‘missing information’ below.

II.A List of important risks and missing information

Important risks of Clopidrion are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Clopidrion. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	• Bleeding disorders • Thrombotic thrombocytopenic purpura • Acquired hemophilia A • Cross-reactive drug hypersensitivity among thienopyridines • Severe cutaneous reactions (including erythema multiform [EM], Stevens Johnson syndrome [SJS], toxic epidermal necrolysis [TEN] and Acute generalized exanthematous pustulosis [AGEP])
Important potential risks	• Reduction in pharmacological activity of clopidogrel in presence of CYP2C19 inhibitor: PPI interaction (omeprazole) and potential clinical consequences • Diminished antiplatelet response of clopidogrel in patients with genetically reduced CYP2C19 function and potential clinical consequences
Missing information	• Use during pregnancy and breastfeeding • Use in children • Use in patients with severe hepatic impairment • Use in patients with severe renal impairment

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

There are no studies required for Clopidrion.